Stéphane Nancey

8.4k total citations
170 papers, 3.3k citations indexed

About

Stéphane Nancey is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Stéphane Nancey has authored 170 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Genetics, 97 papers in Epidemiology and 53 papers in Immunology. Recurrent topics in Stéphane Nancey's work include Inflammatory Bowel Disease (113 papers), Microscopic Colitis (80 papers) and Immunodeficiency and Autoimmune Disorders (23 papers). Stéphane Nancey is often cited by papers focused on Inflammatory Bowel Disease (113 papers), Microscopic Colitis (80 papers) and Immunodeficiency and Autoimmune Disorders (23 papers). Stéphane Nancey collaborates with scholars based in France, United States and Belgium. Stéphane Nancey's co-authors include Bernard Flourié, Gilles Boschetti, Xavier Roblin, Laurent Peyrin‐Biroulet, Dominique Kaiserlian, Stéphane Paul, Driffa Moussata, Nicolas Williet, David Laharie and Émilie Del Tedesco and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Gastroenterology.

In The Last Decade

Stéphane Nancey

159 papers receiving 3.2k citations

Peers

Countries citing papers authored by Stéphane Nancey

Since Specialization

Citations

This map shows the geographic impact of Stéphane Nancey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Nancey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Nancey more than expected).

Fields of papers citing papers by Stéphane Nancey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Nancey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Nancey. The network helps show where Stéphane Nancey may publish in the future.

Co-authorship network of co-authors of Stéphane Nancey

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Nancey. A scholar is included among the top collaborators of Stéphane Nancey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Nancey. Stéphane Nancey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort 2024 ·Journal of Crohn s and Colitis ·Cathérine Reenaers, (unknown), Maria Nachury, David Laharie, Yoram Bouhnik, Mathurin Fuméry, J.M. Gornet, Aurélien Amiot, Romain Altwegg, Martine De Vos, Philippe Marteau, Arnaud Bourreille, Stéphane Nancey, Stéphanie Viennot, Édouard Louis, Magali Svrcek	1
2	Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort 2024 ·Journal of Crohn s and Colitis ·Cathérine Reenaers, (unknown), Maria Nachury, David Laharie, (unknown), Mathurin Fuméry, (unknown), Aurélien Amiot, Romain Altwegg, Martine De Vos, Philippe Marteau, Arnaud Bourreille, Stéphane Nancey, S Viennot, Édouard Louis, Magali Svrcek	1
3	Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study 2024 ·BioDrugs ·Guillaume Bouguen, Laure Gossec, (unknown), (unknown), Guillaume Bonnaud, Xavier Roblin, (unknown), Stéphane Nancey, (unknown), Jérôme Filippi, Lucine Vuitton, Stéphane Nahon, Azeddine Dellal, (unknown), (unknown), (unknown), (unknown), Hubert Marotte	2
4	Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study 2023 ·Clinics and Research in Hepatology and Gastroenterology ·(unknown), Stéphane Nancey, Mélanie Serrero, Ludovic Caillo, Cyrielle Gilletta, Alban Benezech, (unknown), (unknown), (unknown), (unknown), Jean‐François Bourgaux, (unknown), (unknown), Magdalena Meszaros, Romain Altwegg	3
5	Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease 2023 ·Journal of Crohn s and Colitis ·Xavier Roblin, Stéphane Nancey, Konstantinos Papamichael, Gérard Duru, (unknown), (unknown), Adam S. Cheifetz, Nicole Fabien, (unknown), Stéphane Paul	18
6	Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study 2023 ·Alimentary Pharmacology & Therapeutics ·Mathurin Fuméry, Stéphane Nancey, Jérôme Filippi, Romain Altwegg, Xavier Hébuterne, (unknown), (unknown), (unknown), Stéphane Paul, Xavier Roblin	2
7	Role of adherent and invasive Escherichia coli in Crohn’s disease: lessons from the postoperative recurrence model 2022 ·Gut ·Anthony Buisson, Harry Sokol, Nassim Hammoudi, Stéphane Nancey, Xavier Tréton, Maria Nachury, Mathurin Fuméry, Xavier Hébuterne, (unknown), Jean‐Pierre Hugot, Gilles Boschetti, Carmen Stefănescu, Pauline Wils, Philippe Seksik, Lionel Le Bourhis, Madeleine Bezault, Pierre Sauvanet, Bruno Pereira, Matthieu Allez, Nicolas Barnich	33
8	Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy 2021 ·Alimentary Pharmacology & Therapeutics ·(unknown), Gilles Boschetti, Bruno Pereira, Bernard Flourié, Michel Dapoigny, Maud Reymond, (unknown), Claire Gay, (unknown), Anthony Buisson, Stéphane Nancey	33
9	Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease 2021 ·United European Gastroenterology Journal ·Anthony Buisson, Stéphane Nancey, (unknown), David T. Rubin, Xavier Hébuterne, Benjamin Pariente, Mathurin Fuméry, David Laharie, Xavier Roblin, Gilles Bommelaer, Bruno Pereira, Laurent Peyrin‐Biroulet, Lucine Vuitton, (unknown)	34
10	Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients 2020 ·Alimentary Pharmacology & Therapeutics ·(unknown), Anne Bourrier, Maria Nachury, Stéphane Nancey, Yoram Bouhnik, Mélanie Serrero, Laura Armengol‐Debeir, Anthony Buisson, My‐Linh Tran‐Minh, Camille Zallot, Mathurin Fuméry, Guillaume Bouguen, Véred Abitbol, Stéphanie Viennot, Elise Chanteloup, Sylvie Rajca, Nina Dib, Anne-Laure Parmentier, Laurent Peyrin‐Biroulet, Lucine Vuitton, (unknown)	46
11	Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease 2020 ·Digestive and Liver Disease ·(unknown), David Laharie, Stéphane Nancey, Xavier Hébuterne, Mathurin Fuméry, Benjamin Pariente, Xavier Roblin, Laurent Peyrin‐Biroulet, Régine Minet‐Quinard, Bruno Pereira, Gilles Bommelaer, Anthony Buisson	10
12	Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study 2018 ·Alimentary Pharmacology & Therapeutics ·(unknown), Nicolas Williet, Lieven Pouillon, (unknown), Manoel de Carvalho, Stéphane Nancey, Anthony Lopez, Stéphane Paul, Camille Zallot, Xavier Roblin, Laurent Peyrin‐Biroulet	87
13	Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study 2018 ·Alimentary Pharmacology & Therapeutics ·Claire Auzolle, Stéphane Nancey, My‐Linh Tran‐Minh, Anthony Buisson, Benjamin Pariente, Carmen Stefănescu, Mathurin Fuméry, Philippe Marteau, Xavier Tréton, Nassim Hammoudi, (unknown), Xavier Jouven, Philippe Seksik, Matthieu Allez	63
14	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case‐control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) 2018 ·Alimentary Pharmacology & Therapeutics ·Charlotte Gagnière, Anne Bourrier, Philippe Seksik, Jean‐Marc Gornet, Olivier Dewit, Stéphane Nancey, Romain Altwegg, Véred Abitbol, David Laharie, Cathérine Reenaers, Anthony Buisson, Benjamin Pariente, Stéphanie Viennot, Lucine Vuitton, Carmen Stefănescu, Philippe Marteau, Guillaume Bouguen, Jacques Cosnes, Aurélien Amiot, (unknown)	7
15	Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease—A multicenter, retrospective, observational study 2018 ·Digestive and Liver Disease ·Lieven Pouillon, (unknown), Guillaume Pineton de Chambrun, Lucine Vuitton, Benjamin Pariente, Camille Zallot, (unknown), Mathurin Fuméry, Cédric Baumann, Aurélien Amiot, Stéphane Nancey, Hélène Rousseau, Laurent Peyrin‐Biroulet	12
16	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study 2017 ·Alimentary Pharmacology & Therapeutics ·Chloé Martineau, Bernard Flourié, Pauline Wils, Thibaut Vaysse, Romain Altwegg, Anthony Buisson, Aurélien Amiot, Guillaume Pineton de Chambrun, Véred Abitbol, Mathurin Fuméry, Xavier Hébuterne, Stéphanie Viennot, David Laharie, Laurent Beaugerie, Stéphane Nancey, Harry Sokol, (unknown)	23
17	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial 2017 ·Alimentary Pharmacology & Therapeutics ·Xavier Roblin, Gilles Boschetti, Nicolas Williet, Stéphane Nancey, Hubert Marotte, Anne‐Emmanuelle Berger, Jean–Marc Phelip, Laurent Peyrin‐Biroulet, Jean‐Frédéric Colombel, Émilie Del Tedesco, Stéphane Paul, Bernard Flourié	89
18	Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3⁺Regulatory T Cells but Impairs Their Conversion from CD4⁺T Cells 2016 ·Journal of Crohn s and Colitis ·Gilles Boschetti, (unknown), Émilie Bardel, Sophie Collardeau‐Frachon, Rémi Duclaux‐Loras, (unknown), (unknown), Bernard Flourié, Stéphane Nancey, Dominique Kaiserlian	29
19	OP015. Multicentre clinical trial with topical administration of the Toll-Like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis 2015 ·Journal of Crohn s and Colitis ·Raja Atreya, Stuart Bloom, Franco Scaldaferri, Viviana Gerardi, Åsa Karlsson, Thomas Knittel, Jan Kowalski, Milan Lukáš, Robert Löfberg, (unknown), Grażyna Rydzewska, (unknown), Ursula Seidler, Stéphane Nancey, Markus F. Neurath, Christopher J. Hawkey	1
20	P233 Early measurement of fecal calprotectin after intestinal resection is useful to predict postoperative recurrence in patients with Crohn's disease 2014 ·Journal of Crohn s and Colitis ·(unknown), Gilles Boschetti, (unknown), (unknown), Charles Ménard, Jocelyne Drai, Bernard Flourié, Stéphane Nancey	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact